GlassScriptPhysician profile
Alexis Turner
NPI 1295291870
$2,523.54
in general payments reported to CMS, 2019-2025
42 companies · $668 in 2025
The $668 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $271 · 2023: $584 · 2024: $892 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064 · Education: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.10 |
| Education | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $191.29 | 2024-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $187.78 | 2022-2023 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $184.95 | 2023-2025 | Kisqali |
| Pfizer INC. | $172.58 | 2021-2024 | |
| Abbvie INC. | $150.33 | 2022-2025 | |
| Eisai INC. | $139.51 | 2022-2025 | |
| Lilly USA, LLC | $116.05 | 2021-2025 | Jaypirca, Verzenio |
| Merck Sharp & Dohme LLC | $111.06 | 2023-2024 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $109.52 | 2024-2025 | Reblozyl, Opdivo |
| Celgene Corporation | $94.29 | 2022-2024 | Reblozyl, Pomalyst |
| Genzyme Corporation | $81.94 | 2023-2025 | |
| Emd Serono, INC. | $66.55 | 2023-2024 | Bavencio |
| Janssen Biotech, INC. | $56.54 | 2023-2025 | Erleada, Tecvayli, Darzalex |
| Astellas Pharma US INC | $55.03 | 2024-2025 | Xospata, Vyloy |
| Amneal Pharmaceuticals LLC | $53.16 | 2024-2025 | Alymsys, Avastin |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.